Literature DB >> 19449086

The relationship between impairment of voluntary movements and cognitive impairment in Huntington's disease.

Jirí Klempír1, Olga Klempírová, Jan Stochl, Natasa Spacková, Jan Roth.   

Abstract

The relationship between motor symptoms and cognitive impairment in Huntington's disease (HD) is still discussed. We analysed 45 HD patients in various stages using Unified Huntington's Disease Rating Scale motor subscale (voluntary and involuntary components were evaluated separately), verbal memory and executive functions tests. Partial correlations controlling for HD duration and age were used to estimate the relationships among factor scores for motor and cognitive impairment. Voluntary components of motor performance were found to be significantly correlated with verbal short-term memory disturbances (r = -0.361, P = 0.03), with tests of executive functions more dependent on motor performance (r = 0.640, P < 0.01) and also with tests of executive functions less dependent on motor performance (r = 0.461, P < 0.01). Involuntary components did not correlate significantly with any part of cognitive performance.

Entities:  

Mesh:

Year:  2009        PMID: 19449086     DOI: 10.1007/s00415-009-5164-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  39 in total

1.  Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study.

Authors:  Marie-Noëlle W Witjes-Ané; Maria Vegter-van der Vlis; Jeroen P P van Vugt; Jan B K Lanser; Jo Hermans; Aeilko H Zwinderman; Gert-Jan B van Ommen; Raymund A C Roos
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

2.  Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals.

Authors:  J B Penney; A B Young; I Shoulson; S Starosta-Rubenstein; S R Snodgrass; J Sanchez-Ramos; M Ramos-Arroyo; F Gomez; G Penchaszadeh; J Alvir
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

3.  Complex movement behaviour and progression of Huntington's disease.

Authors:  Jürgen Andrich; Carsten Saft; Natalie Ostholt; Thomas Müller
Journal:  Neurosci Lett       Date:  2007-02-11       Impact factor: 3.046

4.  A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.

Authors:  S Siesling; A H Zwinderman; J P van Vugt; K Kieburtz; R A Roos
Journal:  Mov Disord       Date:  1997-03       Impact factor: 10.338

5.  Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease.

Authors:  B Zappacosta; D Monza; C Meoni; L Austoni; P Soliveri; C Gellera; R Alberti; M Mantero; G Penati; T Caraceni; F Girotti
Journal:  Arch Neurol       Date:  1996-06

6.  Huntington's disease affects movement termination.

Authors:  Martin Lemay; Sylvain Chouinard; François Richer; Paul Lesperance
Journal:  Behav Brain Res       Date:  2007-09-19       Impact factor: 3.332

7.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Margaret E O'Rourke; Peg Nopoulos; Henry L Paulson; Jane S Paulsen
Journal:  Ann Clin Psychiatry       Date:  2008 Jan-Mar       Impact factor: 1.567

8.  Thalamic metabolism and symptom onset in preclinical Huntington's disease.

Authors:  A Feigin; C Tang; Y Ma; P Mattis; D Zgaljardic; M Guttman; J S Paulsen; V Dhawan; D Eidelberg
Journal:  Brain       Date:  2007-09-24       Impact factor: 13.501

9.  Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene.

Authors:  C Verny; P Allain; A Prudean; M-C Malinge; B Gohier; C Scherer; D Bonneau; F Dubas; D Le Gall
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

10.  Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study.

Authors:  K A Bamford; E D Caine; D K Kido; W M Plassche; I Shoulson
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

View more
  3 in total

1.  A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.

Authors:  Emilie M André; Gaëtan J Delcroix; Saikrishna Kandalam; Laurence Sindji; Claudia N Montero-Menei
Journal:  Pharmaceutics       Date:  2019-10-12       Impact factor: 6.321

2.  Objective acoustic quantification of phonatory dysfunction in Huntington's disease.

Authors:  Jan Rusz; Jiří Klempíř; Eva Baborová; Tereza Tykalová; Veronika Majerová; Roman Cmejla; Evžen Růžička; Jan Roth
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

Review 3.  Developing stem cell therapies for juvenile and adult-onset Huntington's disease.

Authors:  Kyle D Fink; Peter Deng; Audrey Torrest; Heather Stewart; Kari Pollock; William Gruenloh; Geralyn Annett; Teresa Tempkin; Vicki Wheelock; Jan A Nolta
Journal:  Regen Med       Date:  2015       Impact factor: 3.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.